Cellact Ltd., headquartered in Israel, is a pioneering company in the biotechnology sector, specialising in innovative cell-based therapies. Founded in 2015, Cellact has rapidly established itself as a leader in regenerative medicine, focusing on the development of advanced treatments for various medical conditions. The company’s core offerings include proprietary cell culture technologies and therapeutic solutions that stand out for their efficacy and safety. With a commitment to research and development, Cellact has achieved significant milestones, including collaborations with leading research institutions and successful clinical trials. Recognised for its contributions to the field, Cellact Ltd. continues to expand its operational reach, aiming to transform patient care through cutting-edge biotechnological advancements.
How does Cellact Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Telecommunications Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cellact Ltd.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cellact Ltd., headquartered in IL, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As such, Cellact Ltd. has not established any formal commitments to reduce its carbon footprint or align with industry-standard climate initiatives like the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). Without available data or commitments, it is unclear how Cellact Ltd. is addressing climate change or its carbon emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cellact Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
